Dublin, July 19, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Human Albumin Market 2016-2020" report to their offering. The analysts forecast the global human albumin market to grow at a CAGR of 4.97% during the period 2016-2020. The report covers the present scenario and the growth prospects of the global human albumin market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic albumin drugs used to treat infections, liver diseases, shock, during surgery, and severe burns. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched in the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.
Albumin-based therapies such as Idelvion (CSL654 rIX-FP) by CSL Behring received marketing approval from the US FDA in March 2016 and from the EMA in May 2016. Apart from these, Albutropin (TV-1106) by Teva Pharmaceuticals, Ampion by Ampio Pharmaceuticals, and Albutein by Grifols (for Alzheimer's disease) are expected to enter the market during the forecast period.
A trend helping to propel market growth is the rise in non-therapeutic applications. Non-therapeutic applications of albumin are on a rise. Research is yet to evaluate the applications of albumin as an excipient for commercial use. Some areas where albumin can be employed are as a drug-formulating agent, an ingredient in vaccines and sealant in surgeries, and to coat medical devices and equipment. Though the current supply of albumin for non-therapeutic purposes is low, the high interest shown by the research institutes and pharmaceutical and biopharmaceutical companies in investigating the potential non-therapeutic uses of albumin is expected to drive the market. According to the report, a key driver is the high demand for human albumin in China. China is the largest market for albumin products. Albumin is being used as a volume replacement therapy and for treating kidney diseases, cirrhosis, and cancer. But the demand for plasma products, primarily albumin and immunoglobulins, is outstripping the supply. This is because of the stringent regulations imposed on the supply of raw materials and ban in the import of plasma products. Because of the increased demand for albumin products, the ban on import of plasma products did not include albumin Further, the report states that one challenge that could curtail market growth is the spread of pathogenic contaminants. Key vendors
- CSL Behring - Grifols - Baxalta - Octapharma - Kedrion Other prominent vendors
- AADi - Ablynx - Albumedix - Ampio Pharmaceuticals - Azaya Therapeutics - Beijing Tiantan - Biotest - Bristol-Myers Squibb - Celgene - ConjuChem - GSK - Hebei Changshan Biochem Pharma - HiMedia Laboratories - Hualan Biological Engineering - InVittria - MedxBio - Merck - Mitsubishi Tanabe Pharma - NantBioScience - Novo Nordisk - Novozymes - Shanghai RAAS Blood Products - Sucampo Pharmaceuticals - Teva Pharmaceuticals - Thermo Fisher Scientific - Tianjin SinoBiotech & Beijing Bio-Fortune - Ventria Bioscience - Yoshitomi Pharmaceutical Key Topics Covered: Part 01: Executive summary Part 02: Scope of the report Part 03: Market research methodology Part 04: Introduction Part 05: Plasma therapeutics: An overview Part 06: Global plasma therapeutics market Part 07: Plasma fractionation market Part 08: Albumin: An overview Part 09: Pipeline portfolio Part 10: Global albumin market Part 11: Market landscape Part 12: Market segmentation by application Part 13: Geographical segmentation Part 14: China albumin market Part 15: Market drivers Part 16: Impact of drivers Part 17: Market challenges Part 18: Impact of drivers and challenges Part 19: Market trends Part 20: Vendor landscape Part 21: Appendix
For more information visit http://www.researchandmarkets.com/research/l4...obal_human
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Hematological Drugs